Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer

Allouchery M, Lombard T, Martin M, the French Network of Regional Pharmacovigilance Centers, *et al.* Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer. *J Immunother Cancer* 2020;8:e001622. doi: 10.1136/jitc-2020-001622

This paper has been updated since first published to revise affiliation 10 to '+Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e001622corr1. doi:10.1136/jitc-2020-001622corr1